Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

This study is currently recruiting participants.
Verified January 2014 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00359632
First received: July 28, 2006
Last updated: January 23, 2014
Last verified: January 2014
  Purpose

To understand and characterize the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for six weeks or longer for the development of signs or symptoms of visual disturbance or eye disorders.


Condition Intervention Phase
Optic Nerve Diseases
Drug: Zyvox - linezolid
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Prospective Study Of Ophthalmologic Function In Patients Receiving Linezolid For Six Weeks Or Greater

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • To prospectively identify and characterize optic nerve toxicity in subjects receiving long term (6 weeks or greater) linezolid therapy. [ Time Frame: Up to 1 year after end of therapy ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To evaluate ophthalmologic screening tests to diagnose optic nerve toxicity; To relate occurrence of toxicity to duration of therapy, mitochondrial genetics and other factors; To assess the overall long-term safety of linezolid. [ Time Frame: Up to 1 year after end of therapy ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: November 2008
Estimated Study Completion Date: January 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Linezolid
Subjects have received at least 6 weeks of linezolid therapy (600 mg BID). Continued duration of linezolid treatment is based on treating physician's benefit/risk assessment. A matching control who did not receive linezolid will be selected for each linezolid treated subject.
Drug: Zyvox - linezolid
Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.

Detailed Description:

Characterize Optic Side Effect

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female subjects who are 18 years of age or older.
  • Subjects in Treated Group:
  • Subjects must have received linezolid 600 mg BID for six weeks or greater and be currently on drug (or have received linezolid within 7 days of baseline evaluation).
  • Subjects who have current signs or symptoms compatible with linezolid toxicity (i.e. optic or peripheral neuropathy) may be enrolled in the study if they are on linezolid at time of baseline evaluation (or have received linezolid within 7 days of baseline evaluation).
  • Linezolid may be discontinued at any time at the primary physician's discretion and remain on the study.
  • Women of childbearing potential must use adequate contraception
  • Subjects in Control Group:
  • Subjects will have a diagnosis similar to patients in the treated group and similar important co-morbidities and epidemiologic factors if possible.

Exclusion Criteria:

  • Subject in Treated Group:
  • Subjects with a known presence of optic or peripheral nerve damage due to another illness, condition or medication.
  • Subjects with a pre-existing or a diagnosis at time of screening visit of an ophthalmologic condition that would adversely affect the study testing protocol (e.g. dense cataracts, macular degeneration, retinitis pigmentosa).
  • Subjects who are currently receiving or anticipated to receive another medication, antibiotic or other, that has known potential to produce ocular or neurologic toxicity indistinguishable from that caused by linezolid or lactic acidosis.
  • Subjects with a history of significant exposure, in the opinion of the investigator and with prior discussion with the medical monitor, to medications known to produce optic or peripheral neuropathy.
  • Subjects with an active communicable disease (i.e., tuberculosis assessed as currently communicable) and subjects on active treatment for tuberculosis or other mycobacterial disease that include drugs that have known potential to produce ocular or neurologic toxicity.
  • Subjects with severe liver disease or abnormal liver function test.
  • Subjects in Control Group:
  • Subjects must not currently be taking linezolid or have received it for more than 7 days at any time.
  • Subjects with a known presence of optic or peripheral nerve damage due to another illness, condition or medication.
  • Subjects with a pre-existing or a diagnosis at the screening visit of an ophthalmologic condition that would adversely affect the study testing protocol (e.g. dense cataracts, macular degeneration, retinitis pigmentosa).
  • Subjects who are currently receiving another medication, antibiotic or other, that has known potential to produce ocular or neurologic toxicity indistinguishable from that caused by linezolid or lactic acidosis.
  • Subjects with a history of significant exposure, in the opinion of the investigator and with prior discussion with the medical monitor, to medications known to produce optic or peripheral neuropathy.
  • Subjects with an active communicable disease (i.e., tuberculosis assessed as currently communicable) and subjects on active treatment for tuberculosis or other mycobacterial disease that include drugs that have known potential to produce ocular or neurologic toxicity.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00359632

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

Locations
United States, Arkansas
Pfizer Investigational Site Terminated
Jonesboro, Arkansas, United States, 72401
United States, Florida
Pfizer Investigational Site Terminated
Boynton Beach, Florida, United States, 33426
Pfizer Investigational Site Terminated
West Palm Beach, Florida, United States, 33401
United States, Louisiana
Pfizer Investigational Site Recruiting
New Orleans, Louisiana, United States, 70121
United States, Michigan
Pfizer Investigational Site Completed
Detroit, Michigan, United States, 48202
United States, Minnesota
Pfizer Investigational Site Recruiting
Minneapolis, Minnesota, United States, 55455
United States, Pennsylvania
Pfizer Investigational Site Terminated
Philadelphia, Pennsylvania, United States, 19102
Pfizer Investigational Site Terminated
Pittsburgh, Pennsylvania, United States, 15212
Pfizer Investigational Site Terminated
Pittsburgh, Pennsylvania, United States, 15206
Italy
Pfizer Investigational Site Recruiting
Genova, Italy, 16132
Pfizer Investigational Site Recruiting
Udine, Italy, 33100
Sweden
Pfizer Investigational Site Completed
Stockholm, Sweden, 141 86
Pfizer Investigational Site Completed
Stockhom, Sweden, 141 86
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00359632     History of Changes
Other Study ID Numbers: A5951110
Study First Received: July 28, 2006
Last Updated: January 23, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Optic neuropathy following long-term linezolid use

Additional relevant MeSH terms:
Nervous System Diseases
Optic Nerve Diseases
Cranial Nerve Diseases
Eye Diseases
Linezolid
Oxazolidinones
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 17, 2014